Out of 5 analysts, 1 (20%) are recommending FSTX as a Strong Buy, 4 (80%) are recommending FSTX as a Buy, 0 (0%) are recommending FSTX as a Hold, 0 (0%) are recommending FSTX as a Sell, and 0 (0%) are recommending FSTX as a Strong Sell.
Is Lyra Therapeutics a buy?
There are currently 1 buy rating for the stock. The consensus among Wall Street research analysts is that investors should "buy" Lyra Therapeutics stock.
Is F Star Therapeutics a buy?
F-star Therapeutics has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 7 buy ratings, no hold ratings, and no sell ratings.